%PDF-1.6
%
1 0 obj
<>stream
2021-06-28T08:50:11+05:30
2021-07-20T19:19:17-07:00
2021-07-20T19:19:17-07:00
LaTeX with hyperref package
Acrobat Distiller 10.0.0 (Windows); modified using iText 4.2.0 by 1T3XT
10.1002/cac2.12179
10.1002/(ISSN)2523-3548
3
VoR
10.1002/cac2.12179
application/pdf
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial
uuid:b3f6b5b2-52b4-3c0e-beae-5018772b4463
uuid:ecc9302a-f85f-476b-ac99-b9a0838432fd
endstream
endobj
4 0 obj
<>stream
x\r#ѾSrXeΘ˵lx$]rq$ґ?E98Wq\_7՛[^%,7wfyx]݇[G.jAڥ&-5X}y;Č"KjR67
_n_礩[I[\i<غi`
XU+FHۛ(cWEM毲ܝgJ2e!V-f3_6|-?:gmV?#0媩%,!]^4<)r4Ikh~XZ;TVBK40$sYp5mvbU`L@@~M$|א;Mn7f݂Hwа HҼ E)`k8=YZjGZHEZK _I(r)7+j=HZgN5Y
V)Rv`C07:H?iِ
VYlZ_MۺvUzʮoI
zp$2K7[k.@po%GB7,5HiX6j`GJ(o|0Q\ԒR
LF%Bm4ޥ{H6 FY㪀h)n_Q 4EYuM9Z_qHs
L`n>:
v%\zwW~G4mڽ#n.!;fM=]4F8 _pT(aA_iLQehp8IP1I+ YݠjՒ$"j'